Genfit (US:GNFT) — Company Overview, News & Financial Data
Genfit is a biopharmaceutical company dedicated to developing innovative treatments for liver diseases like NASH.
GNFTGenfit
Company profile
About Genfit
Genfit (EPA:GNFT), (NASDAQ:GNFT) is a biopharmaceutical company dedicated to the discovery and development of innovative treatment solutions for liver diseases and other chronic conditions. Focused primarily on advancing therapeutic and diagnostic approaches, its projects include developing elafibranor for non-alcoholic steatohepatitis (NASH) and a diagnostic test for the early detection of liver disease complications. Genfit is committed to addressing unmet medical needs by bringing novel drugs and technologies to patients worldwide, aiming to improve patient outcomes and quality of life in areas with significant therapeutic gaps.
Snapshot
Public USOwnership
1999Year founded
159Employees
Nord, FranceHead office
Loading Map...
Global footprint
Operations
All Locations
Republic of France
Products and/or services of Genfit
- Elafibranor, a treatment for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), aiming to alleviate liver inflammation and fibrosis.
- NIS4 technology for the non-invasive diagnosis of patients with NASH, facilitating earlier and more accurate detection.
- A diagnostic test for the early detection and management of cholestatic liver diseases, improving patient outcomes through timely intervention.
- Collaboration with Terns Pharmaceuticals to develop and commercialize elafibranor in Greater China, expanding its global reach and access.
- Partnership programs aimed at advancing research and development in liver disease treatments, fostering innovation and breakthroughs in the field.
- Initiatives for patient education and support services, enhancing disease awareness and management for individuals living with liver conditions.
Genfit executive team
- Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board
- Mr. M. Pascal PrigentChief Executive Officer
- Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory Board
- Mr. Thomas BaetzChief Financial Officer
- Mr. Pascal CaiseyChief Operating Officer
- Ms. Sakina Sayah-JeanneChief Scientific Officer
- Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
- Mr. Laurent LannooCorporate Secretary & Director of Legal Affairs
- Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal Affairs
- Ms. Emilie DesodtExecutive Vice President of Human Resources